Best Pharma Consulting Company

 What is IDHIFA? how to use?

IDHIFA is a prescription drug used to treat patients with acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations that have recovered or did not improve after previous treatment. It is not known whether IDHIFA is safe and effective in children.

pharma consulting company

What are the possible side effects of IDHIFA?

IDHIFA can cause serious side effects, including:

See "What is the most important information I should know about IDHIFA?"

The most common side effects of IDHIFA include:

  • nausea
  • Vomiting
  • diarrhea
  • jaundice
  • Decreased appetite

Tell your healthcare provider if there is any change in the color of your skin or whites of the eyes.

pharma consulting company

Your healthcare provider will monitor your side effects during treatment, and if you experience certain side effects, they may tell you to stop taking IDHIFA.

These are not all possible side effects of IDHIFA.

description

IDHIFA (Enanib) is an inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme. Enasidenib is a methanesulfonate salt, its chemical name is: 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl] -6-{[2-(trifluoromethyl) )Pyridin-4-yl]amino} 1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate.

or

2-propanol, 2-methyl-1-[[[4-[6-(trifluoromethyl)-2-pyridyl] -6-[[2-(trifluoromethyl)-4pyridyl] Amino-1,3,5-triazine-2-amino]-, methanesulfonate (1:1). The chemical structure is:

IDHIFA® (enasidenib) tablet structure diagram

The experimental formula is C19H17F6N7O•CH3SO3H (C20H21F6N7O4S), and the molecular weight is 569.48 g/mol. In the entire physiological pH range (pH 1.2 and 7.4), Enasidenib is almost insoluble in aqueous solutions (solubility ≤ 74 mcg/mL).

IDHIFA (enacinib) is a 50 mg tablet (equivalent to 60 mg of etanerib mesylate) and a 100 mg tablet (equivalent to 120 mg of etanerib mesylate) for oral administration. Each tablet contains colloidal silica, hydroxypropyl cellulose, hypromellose acetate succinate, iron oxide yellow, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, Inactive ingredients such as sodium lauryl sulfate, sodium starch glycolate, talc and titanium dioxide.

It is very challenging to find a good pharma consulting company which is rapidly growing with remarkable note, but there are some companies that provides numerous amount of pharmaceutical consulting services

Comments

Post a Comment

Popular posts from this blog

Best Pharma Consulting Company

Image
 Drug Name Atriance 5 mg/ml infusion solution 2. Qualitative and quantitative composition Each milliliter of solution contains 5 mg of Nelarabine. Each vial contains 250 mg of Nelarabine. Excipients with known effects Each milliliter of solution contains 1.770 mg (77 micromoles) of sodium. For a complete list of excipients, see section 6.1. 3. Drug form Infusion solution. Clear colorless solution. 4. Clinical details 4.1 Treatment indications Nelarabine is suitable for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) who have not responded or relapsed after treatment with at least two chemotherapy regimens. Because the number of patients in these conditions is small, the information supporting these indications is based on limited data. 4.2 Modes and methods of administration Nelarabine can only be administered under the guidance of a doctor who has experience in the use of cytotoxic agents. Ontology The complete b...
Read more

Best Pharma Consulting Company

Image
  Indications Instruct VENCLEXTA: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Combine with azacitidine, decitabine or low-dose cytarabine for the treatment of newly diagnosed adult acute myeloid leukemia (AML): 75 years or older, or Patients with comorbidities cannot use intensive induction chemotherapy. Important safety information Contraindications In patients with CLL/SLL, simultaneous use of VENCLEXTA with strong CYP3A inhibitors is contraindicated because it may increase the risk of tumor lysis syndrome (TLS). Tumor lysis syndrome Patients treated with VENCLEXTA developed tumor lysis syndromes, including fatal events and renal failure requiring dialysis. VENCLEXTA can cause rapid tumor reduction, so in all CLL/SLL patients, there is a risk of TLS during the start and the start phase, and during the restart period after the dose is interrupted. Changes in blood chemistry consistent with TLS need to be dealt wi...
Read more

Best Pharma Consulting Company

Image
  About Veenat 400 mg tablets 10 Veenat 400 mg tablets belong to a class of drugs called "anti-cancer drugs" and are mainly used to treat various types of cancer. It is used to treat blood cancers (chronic myeloid leukemia and acute lymphocytic leukemia) and gastrointestinal stromal tumors. Cancer is a genetic change in which our cells divide uncontrollably and spread into surrounding tissues. There are more than 100 kinds of cancer, including blood cancer, lung cancer, breast cancer and so on. 10 Veenat 400 mg tablets contain imatinib, which is mainly used to treat cancer. It works by inhibiting the enzymes responsible for the proliferation of cancer cells and induces cell death (apoptosis). As a result, the growth and spread of cancer cells stopped or slowed down. Take 10 Veenat 400 mg tablets as prescribed by your doctor. It is recommended that you take 10 Veenat 400 mg tablets according to your doctor's condition, as long as your doctor has prescribed it for you. In s...
Read more